Lymphatic malformations (LM), also known as Lymphangiomas, are characterized by the overgrowth of lymphatic vessels during pre-and postnatal development. They are congenital malformations of the lymphatic system, and consist of channels and cystic spaces of varying size and result in the accumulation of fluid, often beneath the skin.
- The prevalence of lymphangiomas has been estimated to be 1.1–5.3 cases/10,000 live births. However, the prevalence appears to be higher when the studies include live-births, terminated pregnancies, and stillbirths: then, the estimate is 30 cases/10,000 in the US (Forrester et al., 2004).
- Based on a study of 3,573 three-year-old children, 43 were found with vascular malformations, yielding a prevalence rate of 1.2%. Among the 43 children with vascular malformation, five (12% or 0.14% of the total study population) had some form of the lymphatic anomaly (either lymphatic malformation
- Lymphatic malformations can be observed in any anatomic region but are more commonly found in lymphatic-rich areas, such as the head and neck (45–52%), axilla, mediastinum, groin, and retroperitoneum. (Elluru et al., 2014).
- Most Lymphatic Malformations are evident at birth or within 2 years. However, in some patients, lymphatic malformations may not become apparent until adulthood.
- It is observed that the males and females are equally affected in the case of Lymphatic Malformations (LM) in the 7MM.
DelveInsight's "Lymphatic Malformations Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Lymphatic Malformations market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Lymphatic Malformations market shares of the individual therapies, a detailed current Lymphatic Malformations treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Lymphatic Malformations Market Share
As per DelveInsight assessments, the market size of Lymphatic Malformations (LM) in the 7MM was found to increase for the study period. Among 7MM, United States accounted for the highest market size of Lymphatic Malformations (LM) in comparison to EU5 and Japan. The market size of Lymphatic Malformations (LM) is anticipated to increase during the study period owing to the increasing prevalent population of lymphatic malformations patients in the 7MM.
The Lymphatic Malformations market analysis section of the report helps to understand the current and forecasted Lymphatic Malformations market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Lymphatic Malformations market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Lymphatic Malformations Therapeutics Market
Management of Lymphatic malformations (LM) is complex and multidisciplinary and depends on expertise and experience. Whilst some lesions may resolve spontaneously, the mainstay of management is to eradicate the lesion while causing minimal damage to adjacent structures. Various treatment modalities such as surgical excision, laser therapy, sclerotherapy, or combination therapy have been proposed in the management of such lesions.
There are no pharmacological therapies currently approved for people with Lymphatic Malformations. Currently, only a few pipeline products are in clinical development for the treatment of Lymphatic Malformations. However, increasing research in this condition along with the launch of emerging therapies during the forecasted period would increase the Lymphatic Malformations market size.
Lymphatic Malformations Companies
- Venthera
- Cerecor
- Protara Therapeutics
And many others.
Lymphatic Malformations Therapies covered in the report include VT30, CERC-006, TARA-002, and many more.
Lymphatic Malformations Epidemiology Forecast
The Lymphatic Malformations epidemiology section covers insights about historical and current Lymphatic Malformations patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Lymphatic Malformations Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Lymphatic Malformations Market Share